Navigation Links
Avicena's HD-02 to Proceed to NIH Sponsored Phase III Huntington's Disease Trial
Date:3/12/2008

eting and look forward to this pivotal assessment of HD-02 as a treatment for slowing Huntington's disease for which there currently is no approved treatment," stated Belinda Tsao Nivaggioli, CEO and Chairman of Avicena. "We are also pleased to further strengthen our on-going relationship with Dr. Steven Hersch, Dr. Diana Rosas, and Dr. Bernard Ravina. We look forward to working with the NCCAM, a Division of NIH, and the Orphan Products Division through their sponsorship of this trial."

"We are very enthusiastic about the study results of HD-02 to date and excited to be advancing it into a Phase III trial," stated lead investigator Dr. Steven Hersch. "This Phase III study will evaluate whether HD-02 can slow the progression of Huntington's disease, and pending positive results, may provide a much needed treatment option to Huntington's patients."

ABOUT HD-02

HD-02 is a novel and proprietary drug candidate for the treatment of Huntington's disease (HD). HD-02 has been granted orphan drug designation in the U.S. Results from a Phase II clinical trial of HD-02, led by Dr. Steven Hersch of Massachusetts General Hospital, were published in the January 24, 2006 issue of Neurology and showed that HD-02 suppressed a Huntington's disease marker. Some researchers have linked this oxidative marker as a measure of cellular injury. Earlier preclinical studies performed by Dr. Flint Beal of Cornell Medical Center and Dr. Robert Ferrante of Boston University, showed that HD-02 has significant neuroprotective effects, such as improved movement, reduced neuropathology, and prolonged survival.

ABOUT HUNTINGTON'S DISEASE

Huntington's disease is a progressive neurodegenerative disease caused by a defective gene that is often inherited from parent to child. This genetic defect causes a widespread deterioration of neurons in those parts of the brain that are responsible for controlling cognitive, emotional and motor functions. This progressive deteriora
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
2. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
3. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
4. Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology
5. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
6. Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
11. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... press,release of 25 February 2009, Arpida communicated that the Board ... for the company,s future. , In ... Board,wishes to update shareholders as follows: At the shareholders, meeting, ... include,the following options or a combination thereof: , , ...
... Call Scheduled for Thursday, March 19, 2009 at 11:00 ... Milestone Scientific Inc. (OTC Bulletin Board: ... announced that it intends to file its 2008 year-end ... with the U.S. Securities & Exchange Commission on Tuesday, ...
... a unit of Oppenheimer Holdings Inc., is pleased to announce ... Banking Department. Brian A. McCarthy has joined the firm ... has more than 20 years of investment banking experience and ... Prior to JPM, Brian spent seven years at Lehman ...
Cached Biology Technology:Board Reviews Strategic Options to Present to Shareholders at Shareholders' Meeting 2Milestone Scientific to Report 2008 Year-End Results on Tuesday, March 17, 2009 2Milestone Scientific to Report 2008 Year-End Results on Tuesday, March 17, 2009 3Oppenheimer Announces the Addition of Several Recent Senior Hires in Investment Banking 2Oppenheimer Announces the Addition of Several Recent Senior Hires in Investment Banking 3
(Date:12/22/2014)... -- The 2014 Holiday Season may be the brightest ... Intelligence reports that the long anticipated floodgates for ... that intensifying demand for smart phones, tablets, and ... a global market of 2.5 billion users with ... According to Maxine Most , ...
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, ... fine-scale differences in genetic ancestry of individuals from across ... Since immigrants first arrived more than four hundred years ... served as a meeting place for peoples from different ... ongoing mixing of peoples with African, European, and American ...
(Date:12/17/2014)... FORT BELVOIR, Va. , Dec. 15, 2014 ... its efforts to make it easier to detect ... supply chain. Today the agency started ... marking. The capability will validate the authenticity of ... supply chain. The new quality control measures will ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
... Maurer, Ph.D., assistant professor of chemistry in Arts ... from the National Institute of Mental Health for ... Neuronal Wiring." Maurer,s long term objective ... of a variety of neuronal wiring processes. He ...
... combination of climate and soil to produce some of ... Prized for their mild taste and sweetness, Vidalia onions ... and relishes. Onion producers in the Vidalia region ... Transplants are grown on farms in high-density plantings, then ...
... composted waste materials and byproducts, such as animal manure, ... necessary nutrient source. Studies have shown that human hair, ... salons, combined with additional compost, is an additional nutrient ... available to crop producers in the past couple years, ...
Cached Biology News:Chemist receives NIH funding to unravel tricks of neuronal wiring 2Vidalia onions: Alternative to hand-transplanting proven effective 2New use for human hair 2
... Model SPD131DDA , Our most chemically resistant ... to handle the rigors and solvents of Combinatorial ... display, dual independent timers, an automatic bleeder valve ... pathway. , , Adjustable Vacuum Level ...
... a dedicated concentrator for efficient drying of ... The integrated system combines the SpeedVac™ Concentrator ... design, automatic pump and rotor control, and ... for heater time), makes the DNA120 indispensable ...
... George Paxinos Affiliation: School of Psychology, The ... Watson Affiliation: Curtin University of Technology, Perth, Australia ... atlas of the rat brain. It is ... mm) revison and extension of the compact 3rd ...
For absolute protein quantification. 4 peptides in 5 vials x 2 nmol per peptide...
Biology Products: